PDCD1 and neoplasm: Although all mice were subjected to two tumours, it can be seen from the growth curves (Fig. 6D) that survival of the majority of mice receiving DMSO (vehicle control) or PD-1 therapy either as a single agent or simultaneously with elraglusib treatment was determined by the intracranial tumour, as the subcutaneous tumours in these animals did not reach the maximum 15 mm in diameter.